GC Biopharma Corp. Environmental Analytics
Environmental and financial analysis dashboard for GC Biopharma Corp.. Industry: MANUFACTURING
Company Overview for GC Biopharma Corp.
Highlights
Showing data for FY2022
Operational Environmental Cost
$15m
Operational Environmental Cost Intensity
1.10%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$2.62m
Decoupling Rate (2020-2022)
-11%
Adjusted EBITDA
$119m
Adjusted EBITDA Margin
8.79%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 20.64% | -6.28% | -7.60% | ||
| 0.18% | 0.23% | 0.20% | 0.20% | |
| 12.02% | 10.15% | 4.90% | ||
| 0.71% | 0.85% | 0.90% | 1.01% | |
| $12m | $14m | $15m | $15m | |
| 13.73% | 6.69% | 2.59% | ||
| 0.89% | 1.08% | 1.10% | 1.21% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
8.79%
Adjusted EBIT Margin
4.98%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$1,385m | $1,294m | $1,353m | $1,263m | |
| -6.57% | 4.61% | -6.67% | ||
$1,234m | $1,091m | $1,220m | $1,203m | |
| 89.12% | 84.33% | 90.11% | 95.25% | |
$151m | $203m | $134m | $60m | |
| 10.88% | 15.67% | 9.89% | 4.75% | |
$106m | $156m | $82m | $1m | |
| 7.63% | 12.03% | 6.08% | 0.08% | |
| ENVIRONMENTAL COST DATA | ||||
$12m | $14m | $15m | $15m | |
| 0.89% | 1.08% | 1.10% | 1.21% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$138m | $189m | $119m | $45m | |
| 9.99% | 14.59% | 8.79% | 3.54% | |
$93m | $142m | $67m | $-14m | |
| 6.75% | 10.95% | 4.98% | -1.13% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.20%
Scope 2 (% of Sales)
0.90%
Operational Environmental Cost Intensity
1.10%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
GC Biopharma Corp. | KR | $15m | 1.10% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $32m | 50.09% | N/A | N/A |
Energy-related activities (3) | $7m | 10.47% | N/A | N/A |
Upstream transportation (4) | $4m | 6.82% | N/A | N/A |
Waste (5) | $1m | 1.25% | N/A | N/A |
Business travel (6) | $0m | 0.78% | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $6m | 9.08% | N/A | N/A |
Processing of products (10) | $0m | 0.03% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $14m | 21.48% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $63m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022